Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in psoriatic arthritis
NCT02141763Phase 1Completed
- Sponsor
- UCB
- Start
- May 2014
- Primary completion
- Aug 2015
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of bimekizumab in psoriatic arthritis (PsA) (5 arms), sponsored by UCB. Primary endpoints: Maximum plasma concentration at steady state at Day 141, Minimum plasma concentration at steady state at Day 141 and 5 more. Started May 2014; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02141763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141763.